This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mallinckrodt Management

Management criteria checks 3/4

Key information

Mark Trudeau

Chief executive officer

US$9.0m

Total compensation

CEO salary percentage	12.1%
CEO tenure	9yrs
CEO ownership	n/a
Management average tenure	4.3yrs
Board average tenure	6.3yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Mark Trudeau's remuneration changed compared to Mallinckrodt's earnings?
Date	Total Compensation	Salary	Company Earnings
Apr 01 2022	n/a	n/a	-US$699m
Dec 31 2021	US$9m	US$1m	-US$723m
Sep 24 2021	n/a	n/a	-US$674m
Jun 25 2021	n/a	n/a	-US$213m
Mar 26 2021	n/a	n/a	-US$1b
Dec 25 2020	US$15m	US$1m	-US$970m
Sep 25 2020	n/a	n/a	-US$2b
Jun 26 2020	n/a	n/a	-US$2b
Mar 27 2020	n/a	n/a	-US$1b
Dec 27 2019	US$15m	US$1m	-US$1b
Sep 27 2019	n/a	n/a	-US$4b
Jun 28 2019	n/a	n/a	-US$3b
Mar 29 2019	n/a	n/a	-US$3b
Dec 28 2018	US$14m	US$1m	-US$4b
Sep 28 2018	n/a	n/a	US$2b
Jun 29 2018	n/a	n/a	US$2b
Mar 30 2018	n/a	n/a	US$2b
Dec 29 2017	US$15m	US$1m	US$2b
Sep 29 2017	n/a	n/a	-US$150m
Jun 30 2017	n/a	n/a	-US$93m
Mar 31 2017	n/a	n/a	US$65m
Dec 30 2016	n/a	n/a	US$208m
Sep 30 2016	US$13m	US$1m	US$489m
Jun 24 2016	n/a	n/a	US$522m
Mar 25 2016	n/a	n/a	US$381m
Dec 25 2015	n/a	n/a	US$335m
Sep 25 2015	US$10m	US$1m	US$235m

Compensation vs Market: Mark's total compensation ($USD8.98M) is above average for companies of similar size in the US market ($USD771.99K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Trudeau (60 yo)

9yrs

Tenure

US$8,975,983

Compensation

Mr. Mark Christopher Trudeau has been the Chief Executive Officer and President at Mallinckrodt plc since June 2013, which filed for bankruptcy protection under Chapter 11 of the U.S. Bankruptcy Code in Oc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Trudeau	President	9yrs	US$8.98m	no data
Hugh O'Neill	Executive VP & Chief Commercial and Operations Officer	2.4yrs	US$3.29m	0.053% $ 905.5
Steven Romano	Executive VP & Chief Scientific Officer	no data	US$3.37m	0.041% $ 700.3
Bryan Reasons	Executive VP & CFO	3.3yrs	US$4.10m	0.0026% $ 43.2
Daniel Speciale	Global Corporate Controller & Chief Investor Relations Officer	4.4yrs	no data	no data
Mark Casey	Executive VP & Chief Legal Officer	4.3yrs	US$4.38m	0% $ 0
Kassie Harrold	Senior VP & Chief Compliance Officer	1.4yrs	no data	0.00014% $ 2.4
Ian Watkins	Executive VP & Chief Human Resources Officer	no data	US$2.15m	0.022% $ 365.6
Mark Tyndall	Senior VP of Government Affairs & Chief Counsel of Litigation	no data	no data	no data
John Einwalter	VP & Treasurer	no data	no data	no data
Stephanie Miller	VP, Corporate Secretary & General Counsel of International	no data	no data	no data
David Keenan	VP of Global External Manufacturing & MD of Mallinckrodt Pharmaceuticals	8.4yrs	no data	no data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: MNKK.Q's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Trudeau	President	9yrs	US$8.98m	no data
Angus Russell	Independent Non-Executive Chairman	7.8yrs	US$490.60k	no data
Kneeland Youngblood	Independent Director	9yrs	US$346.00k	no data
JoAnn Reed	Independent Director	9yrs	US$361.00k	0% $ 0
J. Carroll	Independent Director	9yrs	US$356.00k	no data
David Norton	Independent Director	4.8yrs	US$356.00k	no data
David Carlucci	Independent Director	9yrs	US$341.00k	no data
Paul Rutherford Carter	Independent Director	4.1yrs	US$351.00k	0.024% $ 406.4
Ulrich von Andrian-Werburg	Member of Scientific Advisory Council	4yrs	no data	no data
Anne Michelle Whitaker	Independent Director	4.1yrs	US$346.00k	no data
Jörg Gerlach	Member of Scientific Advisory Council	4yrs	no data	no data
Rashmin Savani	Member of Scientific Advisory Council	4yrs	no data	no data

6.3yrs

Average Tenure

65yo

Average Age

Experienced Board: MNKK.Q's board of directors are considered experienced (6.3 years average tenure).

This company listing is no longer active

Mallinckrodt Management

Management criteria checks 3/4

Key information

Recent management updates

Recent updates

Mallinckrodt Ordinary Shares Deleted from Other OTC

Mallinckrodt plc Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome

Mallinckrodt plc Announces New Retrospective Data on African Americans with Advanced Symptomatic Sarcoidosis Treated with Acthar® Gel (Repository Corticotropin Injection)

Barrack, Rodos & Bacine Announces Summary Notice of Class Action and Proposed Settlement Against Mallinckrodt plc

Mallinckrodt plc Announces the Publication of Findings from Retrospective Medical Records Study Assessing the Real-World Utilization and Outcomes of Acthar Gel

Mallinckrodt Agrees to Pay $234 Million to Settle False Claims Act Case Brought by Whistleblower Law Collaborative Client for Unpaid Acthar Medicaid Rebates

Mallinckrodt plc Provides A Regulatory Update on Terlipressin

Mallinckrodt plc Announces Enrollment of First Patient in Phase 1/2A StrataSOMA Clinical Trial of StrataGraft® for Investigating the Treatment of Full-Thickness Burns

Mallinckrodt plc Announces Results of Retrospective, Observational Medical Chart Review Study Assessing Real World Treatment Outcomes Among Cutaneous T-Cell Lymphoma Patients Who Initiated Therapy with Extracorporeal Photopheresis

Buxton Helmsley Sends Letter to Mallinckrodt plc

Buxton Helmsley Provides Information to the Shareholders

Mallinckrodt plc Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society Treatment Guidelines for Patients with Pulmonary Sarcoidosis

Mallinckrodt Announces U.S. FDA Approval of StrataGraft®

Mallinckrodt Presents Data Evaluating Acthar Gel for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Mallinckrodt plc Presents Data Evaluating Inomax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension

Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Silence Therapeutics plc & Mallinckrodt plc Initiate Work on 3Rd Target

Mallinckrodt Provides Regulatory Update on StrataGraft®

Mallinckrodt plc Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease

Mallinckrodt plc(OTCPK:MNKK.Q) dropped from S&P 500 - Pharmaceuticals (Industry)

Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience

Mallinckrodt plc Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in Covid-19 Patients

Mallinckrodt plc(OTCPK:MNKK.Q) dropped from S&P Global BMI Index

Mallinckrodt Notifies by the Staff of NYSE Regulation to Commence Proceedings to Delist the Ordinary Shares

Mallinckrodt plc to Report Q2, 2020 Results on Aug 04, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age